

SPEAKER 1: Photopheresis was first used in the 1980s by Edelson in the US. The photopheresis responses were very good in patients with CTCL, up to 80%. And further studies have shown consistently that patients with erythrodermic CTCL have responses with ECP of over 60%. This is much improved on other trials, which have shown much lower responses for patients with CTCL. Most of the drugs that we use typically have response rates around 20% to 40%. So photopheresis has therefore been selected as a first-line treatment for patients with the erythrodermic CTCL.